sirolimus
Megjelenés
| Clinical data | |
|---|---|
| Trade names | Rapamune, others |
| Other names | Rapamycin, ABI-009 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth, intravenous, topical |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 14% (oral solution), lower with high-fat meals; 18% (tablet), higher with high-fat meals |
| Protein binding | 92% |
| Metabolism | Liver |
| Elimination half-life | 57–63 hours |
| Excretion | Mostly fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| Chemical and physical data | |
| Formula | C51H79NO13 |
| Molar mass | 914.187 g·mol−1 |
| 3D model (JSmol) | |
| Solubility in water | 0.0026 |
| |
| |
| (verify) | |
Főnév
sirolimus (tsz. sirolimuses)